Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Preferred vendor Β· Learn more
The Thymosin Alpha-1 + LL-37 stack is the most comprehensive immune support peptide protocol, combining adaptive immune modulation with innate antimicrobial defense. TA1 enhances T-cell maturation, NK cell activity, and dendritic cell function. LL-37 (Cathelicidin) is a human antimicrobial peptide that directly kills bacteria, viruses, and fungi while modulating innate immune responses and promoting wound healing. Together, TA1 optimizes adaptive immunity for pathogen recognition while LL-37 provides immediate broad-spectrum antimicrobial activity.
TA1 is the master regulator of adaptive immunity. It promotes T-cell maturation in the thymus, activates NK cells for innate surveillance, enhances dendritic cell antigen presentation, and modulates Toll-like receptors for pathogen recognition. It has been approved in over 30 countries for hepatitis B/C and as a cancer immunotherapy adjuvant, demonstrating its clinical effectiveness.
LL-37 is the only human cathelicidin, serving as the first line of innate antimicrobial defense. It directly disrupts bacterial, viral, and fungal membranes, neutralizes endotoxin (LPS), and activates innate immune cells. While TA1 coordinates the adaptive immune response (which takes days), LL-37 provides immediate antimicrobial coverage, ensuring comprehensive protection from first contact through coordinated elimination.
| Protocol | Compound 1 | Compound 2 | Timing | Duration |
|---|---|---|---|---|
| Standard | TA1 1.6mg 2x/week | LL-37 100mcg daily 5x/week | TA1: Tu/Th, LL-37: M-F | 8-12 weeks |
| Acute | TA1 1.6mg 3x/week | LL-37 200mcg daily | TA1: M/W/F, LL-37: daily | 4-6 weeks |
| Maintenance | TA1 1.6mg 1x/week | LL-37 100mcg 3x/week | TA1: Mon, LL-37: M/W/F | Ongoing |
TA1 has extensive clinical safety data from hepatitis and cancer immunotherapy use.
| Panel | Markers | Timing |
|---|---|---|
| Immune Panel | CD4/CD8 ratio, NK cell count, lymphocyte subsets | Baseline, Week 6, Week 12 |
| Inflammatory | CRP, ESR, ferritin | Baseline, Week 4, Week 8 |
| Vitamin D | 25-OH vitamin D | Baseline |
| Basic | CBC with differential, CMP | Baseline, Week 6 |
CD4/CD8 normalization and NK cell increases are primary TA1 markers. CRP/ferritin track inflammation. Optimize vitamin D to 60-80 ng/mL.
TA1 is an immune modulator, not just stimulant, and can help balance overactive responses. However, initial therapy may temporarily flare symptoms. Start low and monitor. LL-37 should be used cautiously as it can activate mast cells.
Standard course is 8-12 weeks. Then transition to maintenance (TA1 1x/week, LL-37 3x/week). TA1 can be used long-term safely, as evidenced by chronic hepatitis treatment spanning months to years.
TA1 optimizes adaptive immunity (T-cells, NK cells, dendritic cells) while LL-37 provides immediate innate antimicrobial defense. Together they cover both first-line defense and coordinated elimination.
TA1 is an immune modulator, not just stimulant, and can help balance overactive responses. However, initial therapy may temporarily flare symptoms. Start low and monitor. LL-37 should be used cautiously as it can activate mast cells.
Standard course is 8-12 weeks. Then transition to maintenance (TA1 1x/week, LL-37 3x/week). TA1 can be used long-term safely, as evidenced by chronic hepatitis treatment spanning months to years.
TA1 optimizes adaptive immunity (T-cells, NK cells, dendritic cells) while LL-37 provides immediate innate antimicrobial defense. Together they cover both first-line defense and coordinated elimination.
TA1 is an immune modulator, not just stimulant, and can help balance overactive responses. However, initial therapy may temporarily flare symptoms. Start low and monitor. LL-37 should be used cautiously as it can activate mast cells.
Standard course is 8-12 weeks. Then transition to maintenance (TA1 1x/week, LL-37 3x/week). TA1 can be used long-term safely, as evidenced by chronic hepatitis treatment spanning months to years.